All In Biotech

Free tool

FAERS Monitor: Qsymia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022580 or its brand name (Qsymia, Phentermine Hydrochloride, Topiramate). Reports on generic versions are filed under their own applications.

Reports

6,540

Serious

887

14% of reports

Hospitalization

222

Death reported

16

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache408
  • paraesthesia349
  • dry mouth312
  • insomnia311
  • dizziness297
  • weight increased295
  • feeling abnormal263
  • inappropriate schedule of product administration257
  • fatigue232
  • constipation228
  • nausea224
  • anxiety212
  • alopecia180
  • product dose omission issue167
  • vision blurred165

Reports by year received

View as table
YearReports
20122
2013107
2014302
2015398
2016366
2017271
2018183
2019162
2020226
2021262
2022366
2023794
20241,134
20251,186
2026781

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dry mouthSignal31212.411.13,262
paraesthesiaSignal3497.16.51,849
inappropriate schedule of product administrationSignal2574.64.1724
weight increasedSignal2954.23.8734
vision blurredSignal1653.93.3350
insomniaSignal3113.83.4634
feeling abnormalSignal2633.53.1480
constipationSignal2283.43.0380
alopeciaSignal1802.92.6232
anxietySignal2122.42.1173
headacheSignal4082.11.9239
dizziness2971.91.7132
product dose omission issue1671.81.663
fatigue2321.00.80
nausea2240.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.